Seer Bio



HBM contact: Dr Ivo Staijen, Dr Chandra Leo

Company status: public

 Seer’s novel Proteograph™ platform allows for the generation of proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, with a goal of enabling breakthroughs in the most challenging research and clinical problems, such as early disease detection.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171